EICHOR
● Completed
A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
Condition: Choroidal Neovascularization Secondary to Pathologic Myopia · Sponsor: Hoffmann-La Roche
About this study
This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of faricimab in patients with myopic choroidal neovascularization (CNV). This non-inferiority study will compare 6.0 mg faricimab versus 0.5 mg ranibizumab administered at a pro-re-nata (PRN) dosing regimen after an initial active IVT treatment administration at randomization (Day 1).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (63)
| Strathfield Retina Clinic | Strathfield, New South Wales, Australia | — |
| Sydney Eye Hospital | Sydney, New South Wales, Australia | — |
| Sydney Retina Clinic and Day Surgery | Sydney, New South Wales, Australia | — |
| Centre For Eye Research Australia | East Melbourne, Victoria, Australia | — |
| Beijing Hospital of Ministry of Health | Beijing, China | — |
| Beijing Tong Ren Hospital, Capital Medical University | Beijing, China | — |
| Peking Union Medical College Hospital | Beijing, China | — |
| Beijing Tsinghua Changgung Hospital | Beijing, China | — |
| The Second Hospital of Jilin University | Changchun, China | — |
| Zhongshan Ophthalmic Center, Sun Yat-sen University | Guangzhou, China | — |
| The 2nd Affiliated Hospital of Harbin Medical University | Harbin, China | — |
| Qingdao Eye Hospital of Shandong First Medical University | Qingdao, China | — |
+ 51 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06176352